Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) have received a consensus recommendation of “Moderate Buy” from the eight ratings firms that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $49.3333.

Several research firms have weighed in on MLYS. Jefferies Financial Group restated a “hold” rating on shares of Mineralys Therapeutics in a research report on Monday, June 1st. TD Cowen started coverage on shares of Mineralys Therapeutics in a report on Monday, April 27th. They issued a “buy” rating for the company. HC Wainwright restated a “buy” rating on shares of Mineralys Therapeutics in a research report on Monday, June 1st. Wall Street Zen downgraded Mineralys Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Mineralys Therapeutics in a research note on Friday, July 17th.

Key Headlines Impacting Mineralys Therapeutics

Here are the key news stories impacting Mineralys Therapeutics this week:

• Positive Sentiment: Regulatory milestone remains on track: The company reiterated a December 22, 2026 PDUFA target date for lorundrostat, its investigational treatment for hypertension, and said commercial launch preparations are progressing in anticipation of approval. Mineralys second-quarter results and corporate update
• Positive Sentiment: Financial flexibility improved: Management highlighted a strong cash position with funding expected to support operations into 2028. Strategic financing initiatives and the repurchase of the Tanabe royalty obligation also strengthen the long-term economics of lorundrostat by reducing a future royalty burden. Mineralys launch readiness and cash runway
• Positive Sentiment: New medical leadership: Mineralys appointed cardiovascular medicine executive Dr. Terry Ferguson as chief medical officer. He will oversee medical strategy and late-stage clinical activities ahead of the potential lorundrostat launch. Mineralys appoints chief medical officer
• Neutral Sentiment: Short-interest data offered little signal: Reported short interest was zero shares, with a zero-day days-to-cover ratio, suggesting the data does not indicate meaningful short-selling pressure.
• Negative Sentiment: Quarterly loss missed expectations sharply: Mineralys reported a second-quarter loss of $2.85 per share, compared with the analyst consensus estimate of a $0.55 loss. The sizable variance may be weighing on the stock, although the company remains focused on its pre-commercial development and launch activities. Mineralys second-quarter earnings call transcript

Insider Transactions at Mineralys Therapeutics

In other news, insider Eric Warren sold 7,438 shares of the firm’s stock in a transaction dated Tuesday, July 21st. The shares were sold at an average price of $26.87, for a total value of $199,859.06. Following the transaction, the insider owned 38,400 shares of the company’s stock, valued at approximately $1,031,808. This trade represents a 16.23% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Jon Congleton sold 75,000 shares of the firm’s stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $26.14, for a total transaction of $1,960,500.00. Following the completion of the transaction, the chief executive officer directly owned 614,321 shares in the company, valued at $16,058,350.94. This trade represents a 10.88% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 217,313 shares of company stock valued at $5,624,488 in the last three months. Company insiders own 18.94% of the company’s stock.

Hedge Funds Weigh In On Mineralys Therapeutics

Several large investors have recently bought and sold shares of MLYS. Greenland Capital Management LP bought a new position in Mineralys Therapeutics in the second quarter valued at approximately $809,000. E Fund Management Co. Ltd. bought a new stake in shares of Mineralys Therapeutics during the 2nd quarter valued at $297,000. Timothy G. Youngquist 2020 Irrevocable Trust acquired a new position in shares of Mineralys Therapeutics in the 2nd quarter valued at $2,721,000. BlackRock Inc. acquired a new position in shares of Mineralys Therapeutics in the 2nd quarter valued at $158,832,000. Finally, Deutsche Bank AG bought a new position in shares of Mineralys Therapeutics in the 2nd quarter worth $1,589,000. 84.46% of the stock is currently owned by institutional investors and hedge funds.

Mineralys Therapeutics Price Performance

MLYS stock opened at $27.05 on Thursday. The business has a fifty day moving average price of $26.42 and a 200 day moving average price of $27.60. Mineralys Therapeutics has a fifty-two week low of $12.59 and a fifty-two week high of $47.65. The stock has a market capitalization of $2.23 billion, a price-to-earnings ratio of -6.38 and a beta of 0.68.

Mineralys Therapeutics (NASDAQ:MLYS) last announced its earnings results on Wednesday, August 12th. The company reported ($2.85) EPS for the quarter, missing the consensus estimate of ($0.55) by ($2.30). On average, equities analysts expect that Mineralys Therapeutics will post -2.3 earnings per share for the current fiscal year.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.